Prognostic significance of FLT3 1TD and D835 mutations in AML patients

Hematology Journal

Volumn 4, Issue 1, 2003, Pages 41-46

  Sheikhha, Mohammad Hasan ^a   Awan, Abida ^a   Tobal, Khalid ^a   Liu Yin, John Ahman ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

1TD; AML; D835 mutations; FLT3; Prognosis

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLT3 LIGAND; MITOXANTRONE; PROTEIN TYROSINE KINASE; TIOGUANINE; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; ONCOPROTEIN; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; FEMALE; GENE MUTATION; HUMAN; KARYOTYPE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; STANDARD; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TREATMENT PLANNING; WILD TYPE; ACUTE DISEASE; AMINO ACID SEQUENCE; CLASSIFICATION; COMPARATIVE STUDY; ENZYME ACTIVATION; EXON; GENETICS; KARYOTYPING; LIFE TABLE; MIDDLE AGED; MOLECULAR GENETICS; MORTALITY; MYELOID LEUKEMIA; POINT MUTATION; POLYMERASE CHAIN REACTION; RISK; SURVIVAL; TANDEM REPEAT;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AMINO ACID SEQUENCE; COHORT STUDIES; ENZYME ACTIVATION; EXONS; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID; LEUKOCYTE COUNT; LIFE TABLES; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MYELODYSPLASTIC SYNDROMES; NEOPLASM PROTEINS; POINT MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RISK; SURVIVAL ANALYSIS; TANDEM REPEAT SEQUENCES;

EID: 0038266599     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200224     Document Type: Article

References (20)

1. Ullrich A, Schlessinger J.Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61: 203-212.
2. Rosnet O, Schiff C, Pebusque MJ, Marchetto S, Tonnelle C, Toiron Y, et al. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood 1993; 82: 1110-1119.
3. Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem 1988; 57: 443-478.
4. Heldin CH. Dimerization of cell surface receptors in signal transduction. Cell 1995; 80: 213-223.
5. Turner AM, Lin NL, Issarachai S, Lyman SD, Broudy VC. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells. Blood 1996; 88: 3383-3390.
6. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911-1918.
7. Fenski R, Flesch K, Serve S, Mizuki M, Oelmann E, Kratz-Albers K et al. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br J Haematol 2000; 108: 322-330.
8. Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa S, Okuda T et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997; 11: 1605-1609.
9. Kiyoi H, Towatari M, Yokota S, Hamaguchi M, Ohno R, Saito H et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998; 12: 1333-1337.
10. Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, Tjoa TK et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001; 97: 89-94.
11. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001; 97: 3589-3595.
12. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001; 97: 2434-2439.
13. Abu-Duhier FM, Goodeve AC, Wilson GA, Gari MA, Peake IR, Rees DC et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high risk group. Br J Haematol 2000; 111: 190-195.
14. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93: 3074-3080.
15. Rombouts WJ, Blokland I, Lowenberg B, Ploemacher RE. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia 2000; 14: 675-683.
16. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukaemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-1759.
17. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
19. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics FAB, subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59-66.
20. Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 2001; 113: 983-988.